Dudediligence.

Scilex Holding Company

SCLXNASDAQ · Biological Products, (No Diagnostic Substances)
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$14.4MSep ’24$14.9MDec ’24$5.0MMar ’25$9.9MJun ’25$10.6MSep ’25$4.8MDec ’25$8.6MMar ’26$7.6MJun ’26
Net income, by quarter
−$4.4MSep ’24−$6.5MDec ’24−$26.1MMar ’25−$44.0MJun ’25−$257.8MSep ’25−$46.1MDec ’25−$45.6MMar ’26−$115.0MJun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue$31.3M$38.0M$46.7M$56.6M$30.3M
Gross profit$27.7M$27.2M$31.1M$39.9M$125.8M
Operating income−$35.8M−$50.6M−$105.4M−$83.4M−$346.0M
Net income−$88.4M−$23.4M−$114.3M−$72.8M−$374.1M
Operating cash flow−$28.7M−$21.3M−$20.7M$19.3M$3.8M
Free cash flow−$28.7M−$21.3M−$20.7M$19.3M$3.7M
Cash$4.3M$2.2M$3.9M$3.3M$5.0M
Debt$110.0M$0.00$108.4M$34.9M$83.3M
Shares outstanding132.9M141.3M100.0M5.2M7.0M